Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Receivables - Net: 2013-2025

Historic Receivables - Net for Ptc Therapeutics (PTCT) over the last 11 years, with Sep 2025 value amounting to $203.1 million.

  • Ptc Therapeutics' Receivables - Net rose 1.55% to $203.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.1 million, marking a year-over-year increase of 1.55%. This contributed to the annual value of $158.6 million for FY2024, which is 1.41% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Receivables - Net is $203.1 million, which was up 3.54% from $196.1 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Receivables - Net registered a high of $210.5 million during Q1 2025, and its lowest value of $78.8 million during Q2 2021.
  • Its 3-year average for Receivables - Net is $187.2 million, with a median of $196.1 million in 2025.
  • In the last 5 years, Ptc Therapeutics' Receivables - Net surged by 78.86% in 2021 and then dropped by 2.08% in 2024.
  • Ptc Therapeutics' Receivables - Net (Quarterly) stood at $110.5 million in 2021, then spiked by 40.88% to $155.6 million in 2022, then rose by 3.35% to $160.8 million in 2023, then fell by 1.41% to $158.6 million in 2024, then climbed by 1.55% to $203.1 million in 2025.
  • Its last three reported values are $203.1 million in Q3 2025, $196.1 million for Q2 2025, and $210.5 million during Q1 2025.